WCLC 2025 - Posters & ePosters-P1.11.75 A Phase 2 Study of PCSK9 Inhibitor, Alirocumab, and PD1 Inhibitor, Cemiplimab, in Advanced Immunorefractory Metastatic NSCLC

P1.11.75 A Phase 2 Study of PCSK9 Inhibitor, Alirocumab, and PD1 Inhibitor, Cemiplimab, in Advanced Immunorefractory Metastatic NSCLC

Asset Subtitle

Eziafa Oduah

Meta Tag

Speaker Eziafa Oduah

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy